TABLE 2.
ELISPOT screening time pointsa
| Patient | ELISPOT screenings (mo) | HLA type
|
||
|---|---|---|---|---|
| HLA-A | HLA-B | HLA-Cw | ||
| BR111 | 2.5/5.5/7.5/19#/46.5# | 02/23 | 44/44 | 04/05 |
| BR554 | 2#/3.5#/7/11#/19 | 02/31 | 39/51 | 07/15 |
| BR1427 | 2/2.5/4#/14.5# | 26/29 | 15/15 | 02/03 |
| 03-32 | 2/9/26.5 | 01/03 | 08/35 | 04/07 |
a
Time points of ELISPOT screenings for CD8+-T-cell responses (at months posttransmission) are given, and visits that included ELISPOT screening of peptide-stimulated T-cell lines are marked (#). The patients’ HLA types are also indicated.